Technical guide

How to read bioavailability studies

A bioavailability assessment should start with more than an increase expressed as a multiple. The tested formulation, active dose, comparator and sampling period need to be read together. This provides a more reliable basis for ingredient selection and makes clear what the research can actually demonstrate.

Start with the research question

Is the study measuring concentrations in blood, a particular biomarker or a clinical outcome? These are different questions. Higher exposure in a pharmacokinetic study does not, by itself, mean a proportional increase in clinical benefit.

Human studies, laboratory experiments and animal studies also provide different kinds of evidence. A technical presentation should identify the evidence type and show the full study reference alongside the result.

Source: EMA / ICH M13A (2024) — Methodological reference for AUC and Cmax; Purpura et al. (2024) — Randomised crossover vitamin C study

The main measures on the chart

MeasureWhat it describesWhat to check
AUCArea under the concentration–time curve over a specified intervalThe same analyte, sampling interval and units.
CmaxHighest measured concentrationSampling schedule and baseline treatment.
TmaxTime to the highest concentrationDo not treat it alone as evidence of greater efficacy.
Clinical endpointA predefined clinical outcomeIt is distinct from pharmacokinetic measurements.

Source: EMA / ICH M13A (2024) — Methodological reference for AUC and Cmax

Why dose and comparator matter

Capsule weight, total formulation weight including carriers, and active amount describe different quantities. A comparison table should record them separately. Dividing results from separate studies using different doses does not establish a valid absorption multiple.

A claim of “the same effect at a lower dose” requires appropriate research directly comparing the relevant doses and outcome. A study measuring blood concentrations does not automatically establish dose equivalence for a different clinical objective.

Source: EMA / ICH M13A (2024) — Methodological reference for AUC and Cmax

Make the design visible

A 2024 vitamin C study used a randomised, double-blind, placebo-controlled crossover design in 27 participants. It illustrates why the comparator and study design should be presented with the findings.

A 2018 liposomal glutathione study, in contrast, was a one-month pilot involving 12 people. Its lack of a placebo group and small sample affect interpretation. Publication does not remove those design limitations.

Source: Purpura et al. (2024) — Randomised crossover vitamin C study; Sinha et al. (2018) — Liposomal glutathione pilot study

A short record for your technical dossier

When assessing an ingredient with Biontera, consider the manufacturer’s research alongside the identity and specification of the material being offered. A concise evidence record helps procurement and formulation teams work from the same information.

  • Tested commercial formulation, manufacturer and composition.
  • Participant number, design, duration and feeding conditions.
  • Active dose, comparator and primary outcome.
  • Uncertainty in the results, funding disclosure and relevance to the intended formula.

Common questions

Does twice the AUC mean the same clinical effect at half the dose?

No. AUC describes exposure over a defined period. Clinical dose equivalence requires appropriate assessment of the relevant doses and clinical outcome.

Can results from another liposomal product be used?

Relevance to the offered ingredient needs to be demonstrated through composition, manufacturing and other appropriate characteristics. A shared technology name is not sufficient.

Why cite a drug bioequivalence guideline?

It provides a methodological reference for interpreting measures such as AUC and Cmax. It does not establish drug approval or a bioequivalence claim for a food supplement here.

Explore the portfolio

From understanding to selection.

Let’s assess your next formulation.

Share your dosage form, intended amount per serving and estimated annual requirement. We can plan ingredient selection, technical documentation and sample evaluation together.

Discuss documents and samples